Less than six months after Nasdaq debut, Malaysia’s Alps Group pivots to bridge biotech access gap
It is expanding into insurance and education to rebuild valuation and put advanced treatments within reach for more people
[KUALA LUMPUR] Less than six months after its debut on the Nasdaq, Malaysia’s Alps Group is shifting its focus from research to execution, expanding into insurance and education as it seeks to close critical gaps in access to advanced medical technologies.
Alps’ push to build a full-stack ecosystem comes as it navigates the realities of being a newly listed biotech firm.
According to US Securities and Exchange Commission filings and Nasdaq data, Alps Group is in the early stages of commercialisation, reporting 12-month trailing revenue of around US$3.7 million and has yet to achieve profitability.
TRENDING NOW
DBS completes US$1 billion significant risk transfer deal, in first for Singapore bank
Malaysian tycoon Vincent Tan’s sell-downs point to pruning rather than an exit plan
Singapore private housing is ‘decoupling’ from HDB market as buyer pools diverge: NUS survey
Not in education, employment or training: Why more Hong Kong youths are opting out of work
